Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 5/20 | 0.40 |
| ▸ | HTR1D | P28221 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25498043 | 0.82 | SIRT1 (0.51) | HTR1BHTR1DKMT2AMEN1HTR1A | |
| SCHEMBL20602346 | 0.77 | MAPT (0.57) | HTR1BHTR1DKMT2AMEN1NR2E1 | |
| SCHEMBL4895828 | 0.77 | HTR1B (0.39) | HTR1BHTR1DKMT2AMCHR1AR | |
| SCHEMBL25498044 | 0.77 | VPS4B (0.49) | HTR1BHTR1DKMT2AMEN1HTR1A | |
| SCHEMBL25493848 | 0.76 | HTR1D (0.34) | HTR1BHTR1DKMT2AMEN1NR2E1 | |
| SCHEMBL20602071 | 0.75 | AR (0.42) | HTR1BHTR1DKMT2AARMEN1 | |
| SCHEMBL4908357 | 0.75 | SIRT1 (0.60) | HTR1BHTR1DKMT2AARMEN1 | |
| SCHEMBL4902920 | 0.75 | SIRT1 (0.47) | HTR1BHTR1DKMT2AARMEN1 | |
| SCHEMBL20601988 | 0.75 | KDM4E (0.36) | KMT2AMCHR1ARMEN1ALDH1A1 | |
| SCHEMBL23875668 | 0.75 | NR2E1 (0.65) | NR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458121-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-05-21 | — | — | US | disclosed |
| WO-2019005841-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11458121-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC10A1, SLC47A1 | HTR1B 4576/4885HTR1D 4807/4885KMT2A 4605/4885 |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC10A1, SLC47A1 | HTR1B 4576/4885HTR1D 4807/4885KMT2A 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.